Project

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS

Automatically Closed · 2020 until 2022

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2020
End Date
2022
Financing
Industry
Study Design
Phase II
Brief description/objective

Multizentrische Studie bei Patienten mit metastasiertem Nierenzellkarzinom nach Progredienz unter einer Erstli-nientherapie mit ICI/ICI oder ICI/TKI Kombination zur Eva-luation der Wirksamkeit und Verträglichkeit des Tyrosin-kinase Inhibitors Cabozantinib